These habitual market beaters can pull it off again.

AbbVie’s ABBV stock slipped below its 50-day simple moving average (SMA) late last week. The stock has also declined by ...

The drugmaker has plenty to offer investors.

AbbVie is hoping to attract customers with an enticing program.

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.

Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful ...

Biogen (BIIB) stock slips as HSBC downgrades to a Sell equivalent rating as part of an analysis that included an upgrade on ...

AbbVie (NYSE: ABBV) has the highest share price of any stock on this list, at more than $200 each. But don't let the price ...

AbbVie’s latest narrative update leaves its fair value estimate steady at roughly $243.55 per share, even as small tweaks to ...

Dividend investing rewards patience. The best dividend stocks don’t just pay consistently—they raise payouts year after year, ...

Close to two years after AbbVie handed over $48 million for the rights to OSE Immunotherapeutics’ inflammation drug, the Big ...

They could grow into their valuation over the next few years.